aortic stenosis

sapien xt vs. sapien 3 nuevas válvulas percutáneas

New TAVR Devices: Better Results in Bicuspids

Courtesy of del Dr. Carlos Fava. &nbsp; The bicuspid aortic valve is highly anatomically challenging because of valve asymmetric calcification, increased annulus diameter, raphe calcification and ascending aorta dilation. The new valves have shown to improve results, but we still lack data on this group. &nbsp; 301 patients presenting bicuspid aortic valve undergoing transcatheter aortic<a href="https://solaci.org/en/2016/09/14/new-tavr-devices-better-results-in-bicuspids/" title="Read more" >...</a>

reducir costos ffr inducido por contraste

Contrast Induced FFR: Cost and Time Effective Alternative

Courtesy of Dr. Guillermo Migliaro. &nbsp; Fractional flow reserve (FFR) is the radio of two flows expressed as the ratio of two pressures ─ distal pressure across stenosis (Pd) to aortic pressure (pa) ─ obtained only under maximal coronary hyperemia, which is a state of drug induced maximal vasodilation. &nbsp; The gold standard to create<a href="https://solaci.org/en/2016/09/12/contrast-induced-ffr-cost-and-time-effective-alternative/" title="Read more" >...</a>

sapien3 reducción de mortalida

SAPIEN 3: Low One-Year-Mortality in High Risk or Inoperable Patients

In the first PARTNER trial (Placement of Aortic Transcatheter Valves), mortality at one year was 24% for high risk patients and 31% for inoperable patients. A recent report on SAPIEN 3 outcomes at 30 days ─ the last generation balloon expandable valve ─ showed a rather lower adverse events rate. However, additional information at longer<a href="https://solaci.org/en/2016/08/23/sapien-3-low-one-year-mortality-in-high-risk-or-inoperable-patients/" title="Read more" >...</a>

Transcatheter Mitral Valve Replacement

Transcatheter Mitral Valve Replacement: A New Arrow in the Bow

Original Title: Transcatheter Mitral Valve Replacement in Native Mitral Valve Disease With Severe Mitral Annular Calcification: Results From the First Multicenter Global Registry Reference: J Am Coll Cardiol Intv. 2016;9(13):1361-1371. doi:10.1016/j.jcin.2016.04.022 Gentileza del Dr. Agustín Vecchia. The risk underlying the surgical approach to mitral valve replacement in patients with severe mitral annular calcification is high. A<a href="https://solaci.org/en/2016/07/15/transcatheter-mitral-valve-replacement/" title="Read more" >...</a>

valve_in_valve

Valve-in-Valve: High or Low Implantation for Better Outcomes?

Original Title: Transcatheter Replacement of Failed Bioprosthetic Valve. Large Multicenter Assessment of the Effect of Implantation Depth on Hemodynamics after Aortic Valve-in Valve. Reference: Matheus Simonato, et al. Circ. Cardiovasc. Interv 2016;9:e003651 &nbsp; Courtesy of Dr. Carlos Fava. &nbsp; At present, most patients undergoing surgical valve replacement receive a bioprosthetic valve, which lasts from 10 to<a href="https://solaci.org/en/2016/07/12/valve-in-valve-high-or-low-implantation-for-better-outcomes/" title="Read more" >...</a>

Percutaneous mitral valve replacement: First steps

Original Title: Percutaneous Transvenous Transseptal Transcatheter Valve Implantation in Failed Bioprosthetic Mitral Valves, Ring Annuloplasty, and Severe Mitral Annular Calcification. Reference: Eleid MF et al. JACC Cardiovasc Interv. 2016 Jun 13;9(11):1161-74. &nbsp; Courtesy of Dr. Agustín Vecchia. &nbsp; Transfemoral percutaneous transvenous mitral valve implantation is a promising technique and, despite the fact that no devices<a href="https://solaci.org/en/2016/06/16/percutaneous-mitral-valve-replacement-first-steps/" title="Read more" >...</a>

TAVI at 10 Years: First Study to Assess TAVI Long Term Durability

Original Title: First look at long-term durability of transcatheter heart valves: Assessment of valve function up to 10 years after implantation. Presenter: Danny Dvir. &nbsp; Transcatheter aortic valve implantation (TAVI) is being used in increasingly younger patients at low surgical risk, which is why longer survival is expected. The durability of transcatheter aortic prostheses has<a href="https://solaci.org/en/2016/05/19/tavi-at-10-years-first-study-to-assess-tavi-long-term-durability/" title="Read more" >...</a>

New York TAVR Registry: Trends in use and mortality at one year

Original Title: Utilization and 1-Year Mortality for Transcatheter Aortic Valve Replacement and Surgical Aortic Valve Replacement in New York Patients With Aortic Stenosis2011 to 2012. Reference:Hannan EL et al. J Am CollCardiolIntv. 2016;9(6):578-585. Courtesy of Dr. Agustín Vecchia It’s been only 14 years sinceCribierperformed the first transcatheter valve replacement. Today, during 2016, 100,000 patients are expected to<a href="https://solaci.org/en/2016/04/08/new-york-tavr-registry-trends-in-use-and-mortality-at-one-year/" title="Read more" >...</a>

PARTNER 2A: TAVI Not Inferior to Surgery in Intermediate Risk Patients

Transcatheter aortic valve replacement (TAVI) with the new generation balloon expandable valve is at least as good as surgery in intermediate risk patients with severe symptomatic aortic stenosis. For those that can be accessedfemorally, TAVI seems even better than surgery. In all, 2032 intermediate risk patients were randomized in 57 centers to TAVI with Sapien<a href="https://solaci.org/en/2016/04/08/partner-2a-tavi-not-inferior-to-surgery-in-intermediate-risk-patients/" title="Read more" >...</a>

PARTNER 1 in +90 Year Old Patients: TAVI and the Age Paradox

A new analyzis of the PARTNER 1 trial showed that patients over 90 undergoing transcatheter aortic valve replacement (TAVI) show no increase in mortality or major cardiovascular events rates, compared to younger patients. In fact, patients over 90 undergoing TAVI have the same life expectation of someone the same age with no aortic stenosis. In-hospital<a href="https://solaci.org/en/2016/04/08/partner-1-in-90-year-old-patients-tavi-and-the-age-paradox/" title="Read more" >...</a>

Top